The state of Massachusetts currently has 532 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
The Genomic Medicine at VA Study
Recruiting
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
09/29/2022
Locations: VA Boston Healthcare System, Boston, Massachusetts
Conditions: Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Recruiting
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: * Durvalumab * Tremelimumab * Radiation Therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Folfox+Irinotecan+Chemort In Esophageal Cancer
Recruiting
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Liposomal irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer